Skip to main content
ANTEROGEN CO., LTD. logo

ANTEROGEN CO., LTD. — Investor Relations & Filings

Ticker · 065660 ISIN · KR7065660003 KO Manufacturing
Open in API
Filings indexed 267 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 065660

About ANTEROGEN CO., LTD.

http://anterogen.com

ANTEROGEN CO., LTD. is a bio-venture company engaged in the research, development, and commercialization of cell therapy products and orphan drugs. The company specializes in utilizing adult stem cells, particularly adipose-derived mesenchymal stem cells, to create innovative treatments. Its key commercialized products include Cupistem®, an autologous stem cell therapy for Crohn's fistula, and Queencell®. Anterogen's research pipeline extends to applications for musculoskeletal diseases, spinal injuries, and cardiovascular conditions. The company also offers stem cell banking services.

Recent filings

Filing Released Lang Actions
[기재정정]분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” (Quarterly Report) for the period January 1 – March 31 2026, and it contains full financial statements, business overview, notes, revenue breakdowns, risk management disclosures, etc. This is a comprehensive interim/quarterly report rather than a brief announcement or transcript. Therefore it should be classified as an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
[기재정정]사업보고서 (2025.12)
Annual Report Classification · 91% confidence The document is a full “사업보고서” (Korean business report) for the fiscal year 2025 (2025.01.01–2025.12.31), containing comprehensive company overview, business operations, R&D activities, financial statements, capital changes, and detailed performance data. It is not a short announcement or mere attestation, but the complete annual report covering the full year’s financial performance and business description. This aligns with the definition of an Annual Report (10-K). FY 2025
2026-05-15 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is the Korean “분기보고서” (Quarterly Report) for AntroGen Co., Ltd. covering the 27th fiscal period Q1 (2026.01.01–2026.03.31). It includes detailed financial statements, business overview, segment results, risk disclosures, and other substantive interim reporting information. It is not a simple announcement or certification but the full interim report itself. Q1 2026
2026-05-15 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 94% confidence The document is a ‘주식등의 대량보유상황보고서’ (large shareholding report) filed under Korean capital markets law, detailing the number and ratio of shares held, reasons for changes, and shareholder identity. It is clearly a notification of a significant shareholding and its changes, fitting the definition of a Major Shareholding Notification.
2026-04-21 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of an Annual General Meeting (AGM) for the company 'Antrogen'. It details the approval of financial statements, dividend resolutions, and the election of directors and auditors. This falls directly under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides the outcome of shareholder votes at a general meeting.
2026-03-20 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It is submitted to the Financial Services Commission/Korea Exchange. This document specifically details changes to the board of directors, which falls under the 'Board/Management Information' category.
2026-03-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.